comprehensive -WSS

comprehensive

author：leisure time 2025-09-02 08:25:08 - browse：88

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： CDC advisory group OKs chikungunya vaccine

WSS

Information blocking fines are now fair game in health care

FDA panel to weigh safety of artificial wombs for preterm births

Ohio train derailment: Experts on toxic chemical risks

Medicare isn't yet testing food as medicine

Fed up with FDA, ALS advocates consider a take

NEJM study measures Covid brain fog, impact on IQ

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

Psychedelics group wrestles with new pharma identity

Medicare Advantage isn’t working — for anyone

Medicare details structure of new drug price negotiation program

Fed up with FDA, ALS advocates consider a take

Malaria cases in Florida and Texas: Here’s what you need to know

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

In age of alternative facts, a scholarly course on calling out crap

What happened to the House vote on health price transparency?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

hotspot

Childhood vaccination ad campaign launches in the U.K.

Chamber of Commerce, DOJ clash in court over drug prices

People with substance use disorder deserve online privacy

Covid’s new normal has set in amid another rise in cases

The struggle to figure out which patients 'deserve' Wegovy

People with substance use disorder deserve online privacy

leisure time

leisure time

leisure time

focus